Sign in

Private company

Point of Care Nano-Technology, Inc.

Point of Care Nano-Technology, Inc. is a biological products company.1 It is headquartered in Whitehouse Station, New Jersey.1

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersWhitehouse Station, New Jersey1
  • Business address531 Us Hwy 22 East, Suite 232, Whitehouse Station, Nj 088892
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

May 20, 2024, we entered into an asset purchase agreement (the “Agreement”) with Point of Care Nano-Technology, LLC (“Point”).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45-$78.0K in 2023−100% since 2015
-$150.0M-$100.0M-$50.0M02015: -$118.8M-$118.8M20152022: -$73.5K-$73.5K2022−100%2023: -$78.0K-$78.0K2023+6%
Net income465-$78.0K in 2023−100% since 2015
-$150.0M-$100.0M-$50.0M02015: -$118.8M-$118.8M20152021: -$7.5K-$7.5K2021−100%2022: -$688.5K-$688.5K2022+9080%2023: -$78.0K-$78.0K2023−89%
Fiscal year2014201520202021202220232024
Operating expenses$73.5K5$78.0K5
Operating income-$118.8M4-$73.5K5-$78.0K5
Net income-$118.8M4-$7.5K6-$688.5K5-$78.0K5

Compare Point of Care Nano-Technology, Inc. with another company

What it owns

What Point of Care Nano-Technology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4985 Jul 31, 2023$3.2K5 Jul 31, 2022−84.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$118.9K5 Jul 31, 2023$123.5K5 Jul 31, 2022−3.7%

Properties, in its own words

The Company does not own or rent any properties. Our mailing address is a post-office box located at 109 Ambersweet Way, Davenport, FL 33897 and our telephone number is (732) 723-7395. We are currently conducting our business operations out of the residence of our CEO, Mr. DeVito, at no charge to us.

Item 2 of the 10-K filed Oct 29, 2024.3

Former names

  • Alternative Energy & Environmental Solutions, Inc.Oct 25, 2010 to Mar 23, 20152

Timeline

  1. Dec 27, 20248-K Executive or director change10
  2. Jun 10, 20248-K Entered a material agreement; Completed an acquisition or sale; Change in control11
  3. May 31, 20248-K Change of auditor12
  4. Feb 1, 20248-K Change of auditor13
  5. Dec 15, 20228-K Entered a material agreement14
  6. Jun 8, 20228-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events15
  7. Apr 14, 20228-K Entered a material agreement; Completed an acquisition or sale16

Filings

33 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 7 major events, 13 other. The latest 20:

  1. May 23, 2025REVOKED EDGAR
  2. May 23, 2025REVOKED EDGAR
  3. Dec 27, 20248-K POINT OF CARE NANO-TECHNOLOGY, INC. 8-K EDGAR
  4. Dec 23, 202410-Q POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q EDGAR
  5. Dec 16, 2024NT 10-Q POINT OF CARE NANO-TECHNOLOGY, INC. FORM NT 10-Q EDGAR
  6. Dec 12, 202410-Q POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q EDGAR
  7. Dec 5, 202410-Q/A POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q/A, AMENDMENT NO. 1 EDGAR
  8. Dec 3, 202410-Q POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q EDGAR
  9. Oct 31, 202410-K/A POINT OF CARE NANO-TECHNOLOGY, INC. FORM 10-K/A, AMENDMENT NO. 1 EDGAR
  10. Oct 29, 202410-K POINT OF CARE NANO-TECHNOLOGY, INC. FORM 10-K EDGAR
  11. Jun 10, 20248-K POINT OF CARE NANO-TECHNOLOGY, INC. FORM 8-K EDGAR
  12. May 31, 20248-K POINT OF CARE NANO-TECHNOLOGY, INC. FORM 8-K EDGAR
  13. Feb 1, 20248-K POINT OF CARE NANO-TECHNOLOGY, INC. FORM 8-K EDGAR
  14. Jun 12, 202310-Q POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q EDGAR
  15. Mar 21, 202310-Q/A POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q/A, AMENDMENT NO. 1 EDGAR
  16. Mar 15, 202310-Q POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q EDGAR
  17. Dec 15, 20228-K POINT OF CARE NANO-TECHNOLOGY, INC. 8-K EDGAR
  18. Dec 13, 202210-Q POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q EDGAR
  19. Oct 25, 202210-K POINT OF CARE NANO-TECHNOLOGY, INC. 10-K EDGAR
  20. Jun 14, 202210-Q POINT OF CARE NANO-TECHNOLOGY, INC. 10-Q EDGAR

The 33 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Point of Care Nano-Technology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPoint of Care Nano-Technology, Inc.1
  • CIK0001504239
  • Employer ID (EIN)27-28306813
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsJuly 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address531 Us Hwy 22 East, Suite 232, Whitehouse Station, NJ 088891
  • Phone732-723-73951
  • Shares outstanding72,790,621 as of Dec 31, 20248
  • Public float$42.0K as of Jan 31, 20233
  • AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 55253
  • On EDGAR sinceOct 25, 20101
  • Filings93 in all: 10-Q (21), 8-K (16), UPLOAD (8), 10-K (7), CORRESP (7), NT 10-Q (6), S-1/A (6), NT 10-K (4)1
    All 19 form types

    10-K/A (3), 10-12G/A (2), 10-Q/A (2), EFFECT (2), REVOKED (2), S-1 (2), 10-12G (1), 15-15D (1), D (1), DEF 14C (1), PRE 14C (1)

  • Latest filingsAnnual report (10-K) Oct 29, 2024
    Quarterly report (10-Q) Dec 23, 2024
    Latest 8-K (8-K) Dec 27, 2024

Risk factors and legal proceedings

The risks Point of Care Nano-Technology, Inc. names in Item 1A of its 10-K filed Oct 29, 2024: 22 risks under these headings, as written.3

  • We have a limited operational history.
  • Our auditors have expressed substantial doubt about our ability to continue as a going concern.
  • Our operational strategy is changing to be refocused on the Life Sciences space.
  • If we do not generate sufficient cash flow from operations in the future, we may not be able to fund our product development efforts and acquisitions or fulfill our future obligations.
  • Our Acquisition presents many risks, and we may not realize the financial and strategic goals we anticipate at the time of the Acquisition.
  • We will require substantial funding which may not be available to us on acceptable terms, or at all. If we fail to raise the necessary capital, we may be unable to successfully implement our business plans.
  • The life-sciences industry is highly competitive and subject to rapid technological changes. As a result, we may be unable to compete successfully, which would harm our business.
  • If our EZ Saliva products are unable to compete effectively with marketed tests targeting similar indications as our EZ Saliva products, our commercial opportunity will be reduced or eliminated.
  • We currently have no sales and marketing organization. If we are unable to establish a direct sales force in the United States to promote our EZ Saliva products, the commercial opportunity for our products may be diminished.
  • Materials necessary to manufacture our EZ Saliva products may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our EZ Saliva products.
  • If we are unable to adequately protect or expand our intellectual property related to our current or future products, our business prospects could be harmed.
  • General Economic Risks
The other 11 risks
  • Risks Related to Our common stock
  • Our shares of common stock are traded from time to time on the OTC Markets, Inc. Expert Market.
  • The application of the “penny stock” rules could adversely affect the market price of our common stock and increase your transaction costs to sell those shares.
  • FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our common stock.
  • Stockholders should have no expectation of any dividends.
  • Our President and CEO and our two majority stockholders are in a position to control all actions requiring stockholder vote.
  • Management has broad discretion in decision making.
  • Certain provisions in our certificate of incorporation and by-laws, and of Nevada law, may prevent or delay an acquisition of our company, which could decrease the trading price of our common stock.
  • Future sales and issuances of our common stock or could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.
  • We may be at risk of securities class action litigation.
  • Management identified material weaknesses in our internal controls, and failure to remediate it or any future ineffectiveness of internal controls could have a material adverse effect on our business and the price of its common stock.
  • If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.

Legal proceedings

We know of no material, active or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16